News

Published on 22 Mar 2024 on Insider Monkey via Yahoo Finance

Innate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call Transcript


Article preview image

Innate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call Transcript March 21, 2024

Innate Pharma S.A. isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).

Operator: At this time, I would like to welcome everyone to the Innate Pharma Full Year 2023 Financial Results and Business Update Call. Today's conference is being recorded and all lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions] And I will now turn the conference over to Henry Wheeler, Vice President of Investor Relations. Mr. Wheeler, you may begin.

NASDAQ.SNY price evolution
NASDAQ.IPHA price evolution
PAR.SAN price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to Buy

Innate Pharma S.A. Sponsored ADR (IPHA) appears an attractive pick, as it has been recently upgra...

Zacks via Yahoo Finance 10 Apr 2024

Innate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call Transcript

Innate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call Transcript March 21, 2024 Innate Pharma S....

Insider Monkey via Yahoo Finance 22 Mar 2024

Innate Pharma (IPHA) Gains as FDA Lifts Hold on Lymphoma Study

Innate Pharma SA IPHA announced that the FDA lifted the partial clinical hold placed on the lacut...

Zacks via Yahoo Finance 4 Jan 2024

15 Undervalued Defensive Stocks For 2024

In this article, we discuss the 15 undervalued defensive stocks for 2024. To skip the detailed ov...

Insider Monkey via Yahoo Finance 24 Dec 2023

7 Hot Growth Stocks Poised to Triple in 2023

Any investor seeking growth stocks that are poised to triple in 2023 will need a strong appetite ...

InvestorPlace via Yahoo Finance 5 May 2023

ORIC's Christmas Present From Pfizer: A $25m Equity Stake (NASDAQ:ORIC)

By the beginning of November this year, ORIC stock had fallen in value to >$2.5 - a market cap...

Seeking Alpha 22 Dec 2022

Sanofi (SNY) Dupixent Gets CHMP Nod to Eosinophilic Esophagitis

Sanofi SNY and partner Regeneron REGN announced that the Committee for Medicinal Products for Hum...

Zacks via Yahoo Finance 19 Dec 2022

Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's...

Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's...

Investing.com 19 Dec 2022

Innate, Sanofi ink licensing deal for NK cells

Shares of Innate Pharma SA ADR rallied about 35% in premarket trading on Monday after the company...

Market Watch 19 Dec 2022

After Five Years Of Collaboration, Sanofi & Innate Pharma Expand Oncology Pact With Additional...

Innate Pharma SA (NASDAQ: IPHA) and Sanofi SA (NASDAQ: SNY) have expanded their collaboration, wi...

Benzinga via Yahoo Finance 19 Dec 2022